Background: Checkpoint inhibitor pneumonitis (CIP) is a highly morbid complication of immune checkpoint immunotherapy (ICI), one which precludes the continuation of ICI. Yet, the mechanistic underpinnings of CIP are unknown.
Introduction
With recent clinical trials demonstrating clear efficacy for immunotherapy in locally advanced and advanced stage non-small cell lung cancer (NSCLC) as well as other tumors, the use of immune checkpoint inhibitors (ICI) for NSCLC has rapidly increased (1) (2) (3) , becoming standard of care.
However, ICIs are associated with a constellation of toxicities termed immune related adverse events (irAEs). These toxicities include arthritis, colitis, endocrinopathies, and lung injury, the latter termed checkpoint inhibitor pneumonitis (CIP) (4, 5) . Clinically, CIP presents with acute to subacute onset of dyspnea, hypoxemia and pulmonary infiltrates similar to seen in patients with lung injury from acute respiratory distress syndrome (ARDS) (6) . Although CIP can result in high morbidity, it was previously thought to an uncommon complication ICI therapy, with an incidence of around 3-5% (7) , (8) based on clinical trial data. However, recent evidence from our group and others suggest that CIP incidence may be higher in real-world settings(9) , (10) . For instance, using a multi-disciplinary, standardized approach(11), we recently observed an incidence of 19% in a cohort of 205 ICI-treated NSCLC patients (12) . In addition, we also observed an association between CIP development and increased mortality in ICI-treated NSCLC patients (13) .
Despite rising incidence of CIP and its association with increased mortality, the current paradigms for diagnosis and treatment of CIP are largely based on anecdotal evidence, primarily because fundamental knowledge of the pathobiology of CIP is lacking (14) . CIP is diagnosed by the presence of compatible symptoms (shortness of breath, hypoxia, cough), new radiographic infiltrates (which can be either unilateral or bilateral (15, 16) , typically with ground glass and consolidative components - Figure 1 ) and the exclusion of infectious etiologies (with sputum cultures or bronchoalveolar lavage). There are currently no diagnostic biomarkers for CIP, so the diagnosis remains largely one of exclusion. Once diagnosed, clinical severity is used to determine CIP grade (Supplementary table 1 ). For CIP Grade 2 (i.e. symptomatic patients with compatible radiographic infiltrates) and higher, ICI therapy is immediately discontinued and empiric high-steroids are initiated. More targeted, disease-specific therapy is not instituted as first-line treatment for CIP in part because there is currently no available data on the mechanism of lung injury in CIP. Due to the lack of diagnostic and therapeutic options, patients diagnosed with CIP are typically also not eligible for further ICI; this is particularly disadvantageous in patients with ongoing tumor response.
As part of a multi-disciplinary immune-related toxicity (irTox) team (11) engaged in diagnosis, management and study of irAEs following ICI therapy, we prospectively collected bronchoalveolar lavage fluid (BALF) specimens from ICI-treated patients with no evidence of CIP as well as those with suspected CIP. Clinical, laboratory and radiographic data of patients suspected of having CIP were subsequently reviewed by the irTox team and a determination was made as to whether the presenting symptoms were due to CIP or another etiology. Using these specimens, we performed multi-parametric flow cytometric analysis on BALF samples to better understand the landscape of immune dysregulation in CIP. In part due to the lack of available data on the biology of lung injury in CIP, we utilized unbiased clustering analytic techniques to examine our flow cytometric results. Such approaches have the advantage of detecting changes in small cell populations that may otherwise be excluded with manual gating. Importantly, the control group comprised patients who also received ICI but did not exhibit any clinical evidence of CIP at time of bronchoscopy.
Results

BAL lymphocytosis is a hallmark for CIP
Study design as well as baseline clinical characteristics for the patients enrolled in this observational study are shown in Figure 2 and Table 1 , respectively. Clinical grade, management and outcomes data for the 12 patients with CIP are presented in Supplementary Table 2 . We first manually counted BAL cell differentials in a subset of control and CIP samples. We found a relative increase in lymphocytes with a concomitant decrease in monocytes in CIP (Supplemental Figure 2 ) compared to patients without CIP. Notably, BAL neutrophils were not abundant in CIP patients. To further characterize subsets of BAL immune cells, we performed multi-parametric flow cytometric analysis using optimized T-cell and monocyte panels (Supplemental Table 3 ). We initially analyzed these data using traditional gating methods, and similar to our manual cell differentials, found an increase in % T-lymphocytes in CIP ( Figure 3 ). Specifically we found an increase in CD3 + CD4 + cells ( Figure 3A ; p=0.04) and a possible association with increased CD3 + CD8 cells ( Figure 3B ; p=0.073). We also noted a decrease in monocytes, specifically CD3 -CD19 -CD14+ cells (3C; p=0.04). We did not observe any differences in %Tregs (CD3 + CD4 + CD127 lo CD25 + Foxp3 + ) among CIP+ and CIP-patients (data not shown).
Unsupervised clustering reveals differential T-cell subpopulations in CIP
To understand immune cell subpopulations in our samples in more granular detail, we next turned to unsupervised clustering analysis. The total numbers of cells per condition used for our unsupervised analyses are shown in Supplemental Table 4 . We represent the results of our clustering analysis using star charts. As shown in Supplemental Figure 1 , in this graphical representation, groups of cells that share similar cytokine profiles are identified as a node, and represented by a circle, whose diameter reflects the number of cells present within that subpopulation. The cell surface or intracellular MFI for each fluorophore is expressed as a wedge within the circle; the radius of the wedge segment represents the expression level of that particular marker. For instance, in Supplemental Figure 1B , a node with very high PD-1, CD45RA and CD127 expression is shown. Topologically, nodes are arranged by similarity to each other in a cluster map (Supplemental Figure 1C ). Cell subsets occupy distinct areas within a map; for instance, in the T-cell cluster map, as expected, CD4 + and CD8 + cells are clustered together in opposite ends, since they are very distinct from each other (Supplemental Figure   1D -E).
In control, unstimulated T-cells, we observed clustering around two cell populations -CD4 + cells with high PD-1 expression (bottom left, Figure 4A ) and CD8 + cells with moderate PD-1 expression (top right, Figure 4A ). Unstimulated CIP samples exhibited increased CD8 + cell populations compared to unstimulated controls (middle right, Figure 4B ) as well as a local shift in CD4+Treg+ populations (bottom left, Figure 4B ), as discussed in more detail below.
To better understand the specific T-cell subsets that were up/downregulated in CIP, we examined the differential cluster map of T-cell subsets, which highlights only clusters where the magnitude of difference between groups was > 95%. As shown in Figure 5 , in CIP, we observed a significant increase in a CD4 + CD45RA + CD25cells that also expressed CD62L. Since the cytokine profile of resembled that of central memory T cells (Tcm), a non-Treg (i.e. conventional) T cell subpopulation characterized by high CD62L and low CD45RA expression, we performed manual gating for Treg and non-Treg subpopulations (Supplemental Figure 3 ) and observed a significantly higher percentage of Tcm in CIP samples (p=0.01). As mentioned earlier, we observed a shift in CD4 + FoxP3 + cells between unstimulated control and CIP cluster maps. Closer examination of these clusters revealed that while clusters of PD-1 lo CTLA-4 lo Tregs were similarly expressed in both CIP and controls, a subpopulation of Tregs with high PD-1 and CTLA-4 expression was only seen in controls and these effector molecules were downregulated in alveolar Tregs in CIP ( Figure 5 ). Compared to controls, multiple CD8 + TNF-α hi subpopulations were upregulated at baseline in CIP ( Figure 5 ). Ex vivo stimulation of CIP samples polarized T cells towards a Type 1 phenotype with increased TNF-α and IFN-γ production across multiple cell subsets with varying degrees of CD8 expression; these cell populations were not increased in control cells following stimulation (Supplemental Figure 4 ).
In summary, these findings suggest multiple dysregulated T-cell subsets in CIP. At baseline, we observe, in CIP: a) increased Tcm, b) loss of PD-1 hi /CTLA-4 hi CD4 + Tregs and c) upregulation of pro-inflammatory (i.e. TNF-α hi , IFN-γ hi ) CD8 + cells . With stimulation, we observe increased in numbers of CD8 + TNF-α hi subsets and amount of TNF-α expression in stimulated CIP samples compared to controls.
Upregulation of IL-1β hi monocytes in CIP and IL-1RA expressing B-cells in controls
Next, we sought to examine population differences in non-T (i.e. CD3 -) cells. Similar to our T-cell analyses, we represented the results in cluster maps, where the distinct cell populations (e.g. CD14 + monocytes, CD16 + monocytes, B-cells) occupy various regions within the map (Supplemental Figure 5 ). We observed clear differences between unstimulated control and CIP samples ( Figure 6 ). As shown in Figure 6A and 6B, and in closer detail in Figure 7 , two reciprocal populations were upregulated in controls and CIP, respectively. In controls, we observed a large increase in several clusters corresponding to IL-1RA expressing CD86 + B-cells (CD19 + ). While this cluster was downregulated in CIP, a different cluster of IL-1β hi , TNF-α hi CD-11b hi myeloid cells (CD19 neg , CD14 int /CD16 int ) was significantly upregulated in CIP. Similar to our T-cell analysis, we confirmed the presence of a TNF-α hi , IL-1β hi , CD11b hi population in CIP samples with manual gating (Supplementary Figure 6 ) Unlike T cells, we did not observe significant differences in cluster profiles between unstimulated and stimulated cells either in the control or CIP condition (Supplemental Figure 7 )
We also compared to the subpopulations identified above as being significantly different in controls or CIP to the results of a meta-clustering analysis, to determine whether the subpopulations selected to be differentially upregulated in our prior analyses were also identified as distinct populations using an "auto-gating" strategy. As shown in Supplemental Figure 8 
Upregulation of lymphocyte chemoattractants in the BALF of CIP patients
To determine whether BALF cytokines were promoting the cellular phenotypes observed in our flow-cytometry data, we measured key cytokines in the cell-free BAL supernatant ( Figure 8A -C, Supplementary Table 5) . Surprisingly, despite observing an increased number of IL-1β hi cells in our flow analysis, we observed decreased levels of IL-1β in CIP BAL supernatants. We observed no differences in TNF-α levels, but observed increased levels of the Type 1 skewing cytokine IL-12p40. We also measured levels of cytokines involved in recruitment of inflammatory cells to the alveolus. We observed lower levels of IL-8, the classical neutrophil chemoattractant, in CIP. While no differences were observed in levels of monocyte chemoattractant proteins 1 or 4, we observed lower levels of macrophage inflammatory protein-3 alpha (MIP-3α) , a significant increase in levels of the interferon gamma-induced protein 10 (IP-10, or CXCL-10) and a trend towards increased levels of T-cell chemoattractant protein TARC (CCL17; p=0.06).
Discussion
In this study, we describe multiple baseline and functional abnormalities in both lymphoid and myeloid alveolar cell types in patients who developed CIP. These abnormalities involve both upregulation of pro-inflammatory subsets and downregulation of counter-regulatory antiinflammatory process in both T-cells and myeloid cells ( Figure 9 ). In normal adults, the BAL is composed primarily of macrophages (>85%) and lymphocytes (10%) (17) . This is similar to the pattern seen in our control samples (i.e. patients who received ICI but did not have CIP at the time of bronchoscopy), suggesting that ICI therapy alone does not appear to significantly alter the alveolar immune cell pattern. In contrast, we observed a lymphocytosis of > 20% in most of our CIP+ BAL samples. BAL lymphocytosis has been reported in other conditions such as sarcoidosis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia, non-specific interstitial pneumonia (NSIP) and radiation pneumonitis. Our finding of lymphocytosis in the BALF of CIP patients argues for the use of BAL cell count differentials and flow cytometry for CD4+/CD8+ cells as part of the clinical evaluation scheme during BAL in patients with suspected CIP. As no biomarker currently exists for this disease, this represents a translational application of our current findings.
Our unbiased clustering approach identified several subpopulations of T cells that are likely to be playing key roles in the pathobiology of CIP. First, CD4 + central memory subsets (Tcm, CD4 + CD45RA -CD62L + ) were increased in CIP. Tcms have been shown to be more resistant to steroid-induced apoptosis than other conventional T cells, such as effector memory (Tem) T-cells.
Moreover, CD62L + cells play an important role in adhesion to inflammatory sites and can perpetuate injury (18) . Increased Tcm in CIP might explain why some patients fail high dose steroid therapy (we recently reported steroid-refractory disease in up to 40% of CIP patients in our cohort (10)); from a lung injury standpoint, this feature of CIP is unique compared to other lymphocytic pneumonitides, which generally tend to be steroid responsive. The incidence of CIP is significantly higher in patients with underlying non-small cell lung cancer than other cancers, and we have shown(5) that within NSCLC patients, tumor histology further stratifies CIP incidence and risk. These findings, coupled with our current data, suggest that Tcm could be responding to tumor-specific antigens. T-cell receptor (TCR) sequencing of the T-cells subsets in CIP samples will be useful in this regard. Second, a subpopulation of CD4 + cells skewed towards a Type I phenotype with high IFN-γ and TNF-α production is upregulated in CIP. Type I lymphocytes have been linked to several lung diseases including sarcoidosis, hypersensitivity pneumonitis and lung allograft rejection (19) (20) (21) . Thus, the combination of "sticky" lung CD4+ T cells (i.e. CD62L+ CD4 cells) and Type I skewing may be synergistically contributing to lung injury seen in CIP patients.
Third, we observed decreased CTLA-4 and PD-1 expression within Treg (i.e. FoxP3 + ) populations suggesting an attenuated Treg suppressive phenotype. One explanation for our findings is that, in CIP, loss of Treg suppression may be promoting exuberant Th1 T cell responses. We have shown that alveolar Tregs play a pivotal role orchestrating resolution of lung inflammation and are present in humans with lung injury (22) , while others have shown that PD-1 + Tregs are more suppressive to control CD8 + T cells (23) . In addition to PD-1, the lack of CTLA-4 may further impair Treg ability to control conventional T-cell (such as Tcm) and macrophage pro-inflammatory responses (24) . Overall, our findings suggest a highly activated alveolar T cells with loss of a regulatory, anti-inflammatory Treg suppressive phenotype contributing to unchecked immune dysregulation seen in CIP.
Interestingly, while we observed decreased numbers of CD14 + monocytes based on traditional gating methods, our clustering data show additional dramatic shifts in myeloid populations between controls and CIP, such as a significant increase in CD11b hi IL-1β hi , myeloid cells with varying degrees of CD14/CD16 expression. This is accompanied by a loss, in CIP, of IL-1RA + CD19 + cells, reflected in the cluster maps as a relative upregulation of these cells in controls.
These findings suggest that an imbalance in IL-1 signaling, along with overexuberant TNF-α signaling may be contributing to the pathobiology of lung injury in CIP. The concomitant presence of increased Tcms, as discussed earlier, may also serve to augment T-cell and monocyte inflammation.
Our BALF cytokine results also point towards a pro-inflammatory, chemoattractant cytokine milleu. Interestingly, we observed a decreased in soluble IL-1β while an increase in IL-1β expressing monocyte subsets was observed in flow cytometry. However, the dynamics of IL-1β production and release is complex and thought to be related to the strength of the inflammatory stimulus (25) . Thus, one possibility is that, in CIP, the underlying source of inflammation promotes IL-1β translation and endosomal storage, but not membrane release. Another possibility is that soluble IL-1β release occurs earlier in injury, and is decreased by the time our samples are obtained (generally 2-3d at a minimum, after onset of symptoms). This lack of time resolution in our BALF data may also explain why TNF-α levels were not significantly different; another explanation is that, while our controls did not have CIP, they underwent bronchoscopy prior to tumor sampling/resection; this bias may be skewing our control IL-1β results. Despite this, our IL-12p40 and CXCL-10 (IP-10) data further implicate CD4 cells in the pathobiology of CIP. IL-12 is a known orchestrator of tissue inflammation and Type I polarization. IL-12p40 can form heterodimers with IL-12p70 and IL-23 (26) ; however neither of these cytokines were elevated in the BALF OF CIP subjects ( Supplementary Table 5 ). Thus, we postulate the increased IL-12p40 observed in CIP constitutes the monomeric form. This secreted form has been reported to be 10-20 fold in excess compared to IL-12p70 in stimulated human peripheral blood cells (27) , and has been to be elevated in asthmatics during airway inflammation (28) . Additionally CXCL-10 (IP-10) are known to guide Tcm lymphocytes (a T cell subset seen to be upregulated in our flow cytometry data) to their destination within lymph nodes (29) . Therapeutically, antibody-mediated blockade of IL-12p40 and CXCL10 have been used to treat inflammatory diseases (30, 31) . Our chemotactic cytokine data collectively reflect a lack of neutrophil chemoattraction to the lung (decreased IL-8).
Similarly, MIP-3α, which is decreased in CIP BALF, has been previously observed in the context of airway infections (32) , is thought to have antimicrobrial properties. This observation, along with our IL8 data and lack of significant neutrophil predominance in our BAL cell differentials ( Supplementary Figure 2) further support the notion that CIP may not be a bacterial infectiontriggered phenomenon. Lastly, our finding of increased CCL17 (TARC) levels correlates with our flow cytometric finding of increased CD11b hi populations of myeloid cells; CD11b + cells have been previously identified as a key source of the CCL17 honing chemokine in the lung (33) .
Our findings suggest several targets for therapeutic consideration in steroid-refractory CIP. We note upregulation of several TNF-α hi subsets (lymphoid and myeloid) at baseline in CIP; this finding provides some tissue-specific rationale for the use of infliximab for steroid-refractory CIP, although our BAL cytokine data suggests that timing of TNF-α inhibition may need to further explored. Importantly, our data also identifies several novel populations upregulated in CIP (such as CD62L hi Tcms and IL-1β expressing monocytes) that could be targeted using existing therapies. Anti-CD62L antibodies or small molecule inhibitors have been used to attenuate models of lung injury(34) , (35) , although these inhibitors are not currently approved for any clinical indication. Biologicals against IL-1β (e.g. anakinra or canakinumab) are currently either in trials or in use, and thus, further validation of these results could provide the rationale for testing these therapies either as first line adjuncts or as salvage therapies for high grade CIP. It is known that transient expression of IL-1β can induce lung inflammation, increase TNF-α and contribute to progressive tissue fibrosis (36) ; hence targeting IL-1β could represent an attractive target in CIP.
CCL-17 (TARC) is the ligand for CCR4 is usually considered a selective chemoattractant for Type 2 cells, although it has been shown to be elevated in sarcoidosis, a classical Type I -mediated lung disease (37) . Blocking TARC or its receptor CCR4 could decrease T cell infiltration into the inflamed CIP lungs. Alternatively, transiently enhancing Treg suppressive function could lead to multiple beneficial effects, such as improving control of exuberant Type I responses and limiting proliferation, abrogating macrophage pro-inflammatory responses and ultimately orchestrating lung repair (22) , (38) . For instance, we have previously shown that short course administration of DNA methyl transferase inhibitor decitabine can potently augment endogenous Tregs and mediate resolution of lung inflammation and promote lung repair (39) . Analysis of CIP rates in ongoing trials utilizing ICI/DNA methyltransferase inhibitor combinations could provide further insight into a potential beneficial effect for these agents from a CIP standpoint.
While our data provides new insight into potential pathobiologic mechanisms in CIP, CIP is unique in comparison to other irAEs with regards to incidence (across cancer types)(40) and relationship to OS. CIP is much more common in lung cancers compared to other cancers, and while other irAEs have been associated with improved OS, we did not observe a similar association with CIP(13). Thus, we do not believe that our results are necessarily generalizable to other irAEs.
There are several limitations to this study. First, due to the logistical challenges associated with identifying and promptly performing lavage in patients with suspected CIP before antibiotic or steroid administration, our samples sizes are low, and thus preclude adjustment for clinical comorbidities (such as COPD) that may confound our results. Second, while only patients with negative infectious work-up were included in the CIP cohort, it is possible that BAL cultures did not identify a focus of infection in patients thought to have CIP. Third, while BAL of CIP infiltrates were performed in areas not previously affected by tumor, it is possible that presence of malignancy in the nearby airways could have influenced our results.
In conclusion, our data provide several hypothesis-generating insights into the dysregulated alveolar immune dysregulation in CIP. In the absence of a pre-clinical model for CIP, our finding provide the first rigorous report of immunological mechanisms underlying CIP. In addition to validation in larger clinical cohorts, these data could inform design of pre-clinical and translational studies aimed at further understanding the mechanistic basis of CIP, so that targeted therapies can be developed for this morbid complication of immunotherapy.
Methods
Study Population:
Patients were enrolled in this prospective observational study if they were a) diagnosed with NSCLC and b) treated with immune checkpoint inhibitors. Patients who received neo-adjuvant ICI underwent bronchoscopy with collection of BALF prior to surgery. Otherwise, BALF was collected whenever patients underwent bronchoscopy. If CIP was suspected, the BALF sampled was categorized as "CIP" if i) the sample was obtained prior to initiation of steroids and antibiotics and ii) a clinical diagnosis of CIP was adjudicated by the multi-disciplinary irTox team (see below). Following adjudication, patients with CIP were treated with high-dose steroids (1mg/kg Prednisone). Second line agents (Infliximab, IVIG or mycophenolate mofetil) were added at the discretion of the treating team if no improvement was noted after 72 hours, as described previously (12) . 
Bronchoalveolar Lavage:
In control patients, the middle lobe was lavaged. In patients with CIP, an area with new infiltrates not previously known to be associated with tumor was lavaged. The volume of instilled and returned saline was abstracted from the BAL procedure note. BAL specimens were processed with ammonium-chloride-potassium (ACK) lysis solution. Cells were then counted following Trypan blue staining to exclude dead cells.
Manual Cell Differentials: BALF cells were stained with Diff quik and equal numbers of total cells (n=500) were counted per specimen by two investigators blinded to the sample group classification as previously described (22) . Figure 1A . All MFI values are compensated, scaled and transformed as previously described (43, 44) . For both T-cells (i.e. singlet, live, CD3 + cells) and monocytes/B-cells (i.e. singlet, live, CD3 -) cells, the cluster map was first constructed on a concatenated dataset composed of unstimulated control, stimulated control, unstimulated CIP and stimulated CIP samples. This concatenated set represents the sum total of biological replicates (n=18; 6 controls and 12 CIP cases). Next, group comparisons between controls and CIP as well as unstimulated and stimulated samples were made by generating group-specific cluster maps as well as a differential cluster map, where a node was considered to be upregulated if there was a >95% difference between groups. As the initial conditions for the clustering algorithm is randomly chosen, the map shape can differ slightly with each run; each analysis was re-run 5 times to ensure that the same clusters were upregulated across multiple runs (map stability). Lastly, a meta-clustering analysis was performed. This represents an "auto- 
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